Versartis, Inc. (NASDAQ:VSAR) issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.78), Briefing.com reports. During the same quarter last year, the business earned ($0.92) earnings per share.
Versartis (NASDAQ VSAR) opened at $1.77 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.39 and a current ratio of 2.39. Versartis has a fifty-two week low of $1.60 and a fifty-two week high of $24.00.
VSAR has been the topic of several research reports. BidaskClub lowered Versartis from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. Cantor Fitzgerald set a $34.00 target price on Versartis and gave the company a “buy” rating in a research note on Thursday, July 27th. Canaccord Genuity set a $28.00 target price on Versartis and gave the company a “buy” rating in a research note on Friday, July 28th. Zacks Investment Research lowered Versartis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Finally, ValuEngine lowered Versartis from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $7.22.
In other Versartis news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the firm’s stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $3.29, for a total value of $7,007,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders sold 2,132,769 shares of company stock valued at $7,014,761. Corporate insiders own 10.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Versartis, Inc. (NASDAQ:VSAR) Posts Earnings Results, Misses Expectations By $0.78 EPS” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/11/12/versartis-inc-vsar-posts-earnings-results-misses-estimates-by-0-78-eps.html.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.